They have mentioned talks with Partners in previous Announcements,
This one was mentioned in their 11 July 2019 Shareholder Update:
"The positive outcomes from the 009 trial also mean that Biotron has been meeting with key potential partners with compelling Phase 2 data in hand. Phase 2 is generally considered the best time to license technology to a major pharmaceutical company as they have the expertise and resources necessary for late stage clinical development and regulatory approvals in major markets such as the USA."
BIT Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
